ML-SYS / 2026.07NON-CLINICAL RESEARCH MATERIALSORIGIN DECLARED BY LOT

← Compound index

RM-IMM / Immune and host-defense signaling

Enfuvirtide

Also known as: T-20 · Fuzeon

Approved comparator exists

Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.

What this is

Enfuvirtide is a synthetic peptide derived from an HIV-1 gp41 sequence and acts as a fusion inhibitor.

Evidence position

The regulated kit supports Grade A for that finished product.

What the record does not establish

The product label is not supplier approval or lot evidence for separately sourced material.

Sources

  • 01
    Fuzeon prescribing informationDailyMed / U.S. National Library of Medicine
    Shows
    U.S. label for a defined enfuvirtide kit and formulation
    Does not show
    Does not authenticate another peptide sample or formulation

External database index

LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE

Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.

PUBMED / FOUND RECORDS

  1. Enfuvirtide.Expert opinion on investigational drugs / 2002 DecPMID 12457443 / DOI 10.1517/13543784.11.12.1837
  2. Enfuvirtide. / 2012PMID 31644169
  3. Enfuvirtide.Drugs / 2003PMID 14664654 / DOI 10.2165/00003495-200363240-00005
  4. Enfuvirtide.Nature reviews. Drug discovery / 2003 MayPMID 12755128 / DOI 10.1038/nrd1091
  5. Enfuvirtide.Drugs of today (Barcelona, Spain : 1998) / 2004 MarPMID 15148534 / DOI 10.1358/dot.2004.40.3.820089

CLINICALTRIALS.GOV / FOUND RECORDS

  1. Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 InfectionCOMPLETED / PHASE3 / National Institute of Allergy and Infectious Diseases (NIAID)NCT00050856 / DIRECT intervention MATCH: Enfuvirtide
  2. Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral LoadCOMPLETED / PHASE3 / French National Agency for Research on AIDS and Viral HepatitisNCT00454337 / DIRECT title MATCH: Enfuvirtide
  3. A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 StudyCOMPLETED / PHASE2 / Tibotec Pharmaceuticals, IrelandNCT00128830 / DIRECT intervention MATCH: Enfuvirtide
  4. A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected AdultsCOMPLETED / PHASE2 / Hoffmann-La RocheNCT00002239 / DIRECT intervention MATCH: Enfuvirtide
  5. Raltegravir in Patients With End Stage Liver Disease and in Transplant RecipientsCOMPLETED / PHASE1, PHASE2 / ANRS, Emerging Infectious DiseasesNCT01022476 / DIRECT title MATCH: Enfuvirtide

Related compounds

RM-IMM

LL-37

Read entry →
RM-IMM

Thymosin alpha 1

Read entry →